国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (6): 420-.doi: 10.3760/cma.j.issn.1673-422X.2017.06.005

• 论著 • 上一篇    下一篇

C1orf63基因在乳腺癌中的表达及其临床意义

李绪渊,洪超群   

  1. 515041 广东省汕头市中心医院肿瘤内科（李绪渊）；汕头大学医学院附属肿瘤医院实验室（洪超群）
  • 出版日期:2017-06-08 发布日期:2017-06-16
  • 通讯作者: 洪超群 E-mail:351266467@qq.com
  • 基金资助:

    Breast neoplasms|Prognosis|C1orf63

Expression and clinical significance of C1orf63 in breast cancer

Li Xuyuan,Hong Chaoqun   

  1. Department of Medical Oncology, Shantou Central Hospital of Guangdong Province, Shantou 515041, China
  • Online:2017-06-08 Published:2017-06-16
  • Contact: Hong Chaoqun E-mail:351266467@qq.com

PDF

946

摘要： 目的探讨C1orf63基因在乳腺癌中的表达及其临床意义。方法采用免疫组织化学法检测C1orf63基因在67例乳腺癌组织标本及癌旁正常组织的表达水平，采用χ2检验分析C1orf63表达与临床病理特征的关系，Cox回归模型进行预后因子分析。结果C1orf63基因在乳腺癌组织的阳性表达率为31.3%（21/67），而在癌旁正常组织中不表达，差异有统计学意义（χ2=24.90，P＜0.01）。C1orf63表达水平与患者年龄（χ2=0.06，P=0.79）、T分期（χ2=0.50，P=0.47）、N分期（χ2=1.41，P=0.23）、TNM分期（χ2=0.29，P=0.58）、雌激素受体（χ2=0.82，P=0.36）、孕激素受体（χ2=0.31，P=0.57）、人表皮生长因子受体2（Her2）表达（χ2=0.00，P=0.98）均无关。多因素预后分析显示N分期（HR=4.96，95%CI为2.03～12.15，P＜0.01）和C1orf63基因（HR=2.37，95%CI为1.05～5.37，P=0.04）是不良预后因素。结论C1orf63基因在乳腺癌组织中的高表达可能提示不良预后。

关键词: 乳腺肿瘤, 预后, C1orf63

Abstract: ObjectiveTo investigate the expression and clinical significance of C1orf63 in breast cancer. MethodsSixtyseven breast cancer tissues and adjacent noncancerous tissues were collected, and the expression of C1orf63 was detected by immunohistochemistry. The relationships between C1orf63 and clinical pathological characteristics were examined with χ2 test. Independent prognostic factors were performed by the Cox regression model. ResultsPositive cytoplasmic expression of C1orf63 was observed in 21 (31.3%) of 67 primary tumors, but not in their matched adjacent noncancerous tissues, with significant difference (χ2=24.90, P＜0.01). There were no relationships between C1orf63 and age (χ2=0.06, P=0.79), T stage (χ2=0.50, P=0.47), N stage (χ2=1.41, P=0.23), TNM stage (χ2=0.29, P=0.58), estrogen receptor (χ2=0.82, P=0.36), progesterone receptor (χ2=0.31, P=0.57), and human epidermal growth factor receptor 2 (Her2) expression (χ2=0.00, P=0.98). Multivariate analysis demonstrated N stage (HR=4.96, 95%CI: 2.0312.15, P＜0.01) and C1orf63 (HR=2.37, 95%CI: 1.055.37, P=0.04) were unfavorable prognostic factors. ConclusionThe high expression of C1orf63 in breast cancer may indicate poor prognosis.